Clinical Trial Goal
To find out:
- The highest dose of nivolumab that’s safe to give with relatlimab
- If the combination of nivolumab and relatlimab is safe and works well to treat lymphoma that has relapsed or is refractory in children and young adults
You may be able to join this trial if you:
- Are 30 years old or younger
- Have lymphoma that has relapsed or is refractory. Some examples include:
- Anaplastic large cell lymphoma (ALCL)
- Cutaneous T-cell lymphoma (CTCL)
- Diffuse large B-cell lymphoma (DLBCL)
- Follicular lymphoma
- Hodgkin lymphoma
- Mantle cell lymphoma (MCL)
- Marginal zone B-cell lymphoma (MZL)
- Mediastinal gray zone lymphoma (MGZL)
- Peripheral T-cell lymphoma (PTCL)
- Primary mediastinal B-cell lymphoma (PMBCL)
- Small lymphocytic lymphoma (SLL)
- Waldenström's macroglobulinemia
- Other T-cell lymphoma
- Do not have lymphoma that doctors consider aggressive. Some examples include:
- Burkitt lymphoma
- Lymphoblastic lymphoma
- NK cell lymphoma
- NK cell leukemia
- T cell leukemia
- T cell lymphoma
- Do not have lymphoma in your brain or spinal cord
- Have not had an autologous (your own cells) or allogeneic (cells from a donor) blood or marrow transplant (BMT)
- Have not been treated with any of the following. Your doctor can tell you this:
- An anti-CTLA-4 antibody
- A drug that targets T-cells
- A lymphocyte activation gene-3 (LAG-3)
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
Nivolumab is a checkpoint inhibitor that targets PD-1 on certain cells.
Relatlimab is a monoclonal antibody that targets LAG3 on certain cells.
You'll get:
Relatlimab is a monoclonal antibody that targets LAG3 on certain cells.
You'll get:
- Nivolumab – Given as intravenous (IV) infusions. The dose you'll get depends on when you start the trial and how safe it has been
- Relatlimab – Given as IV infusions. The dose you'll get depends on when you start the trial and how safe it has been
You may continue treatment for as long as the clinical trial doctors think it’s best for your health. You'll have scans to see how well the treatment is working. The clinical trial doctors will check your health for up to 2 years.
The Food and Drug Administration (FDA) has approved all of the drugs used in this trial. Using them in this way to treat Hodgkin lymphoma and NHL is new and unproven.
Contacts
BMS Study Connect Contact Center www.BMSStudyConnect.com, 855-907-3286, Clinical.Trials@bms.com
First line of the email MUST contain NCT # and Site #.
Locations
Sponsors
lead: Bristol-Myers Squibb
